MCID: ADR004
MIFTS: 46

Adrenal Cortical Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Cortical Adenocarcinoma

MalaCards integrated aliases for Adrenal Cortical Adenocarcinoma:

Name: Adrenal Cortical Adenocarcinoma 12 15
Adrenal Cortex Adenocarcinoma 12
Adrenocortical Carcinoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3959

Summaries for Adrenal Cortical Adenocarcinoma

Disease Ontology : 12 An adrenocarcinoma that originates in the cortex of the adrenal gland and derives from epithelial cells of glandular origin.

MalaCards based summary : Adrenal Cortical Adenocarcinoma, also known as adrenal cortex adenocarcinoma, is related to legius syndrome and cholangiocarcinoma, and has symptoms including fever and flank pain. An important gene associated with Adrenal Cortical Adenocarcinoma is SPRY2 (Sprouty RTK Signaling Antagonist 2), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal gland and adrenal cortex, and related phenotypes are Decreased cell migration and Decreased viability with paclitaxel

Related Diseases for Adrenal Cortical Adenocarcinoma

Diseases related to Adrenal Cortical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 legius syndrome 9.9 SPRY1 SPRY2
2 cholangiocarcinoma 8.7 EGF MAPK3 MME PTEN

Symptoms & Phenotypes for Adrenal Cortical Adenocarcinoma

UMLS symptoms related to Adrenal Cortical Adenocarcinoma:


fever, flank pain

GenomeRNAi Phenotypes related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.26 MAPK3 RPS6KA1 SPRY1 CBL
2 Decreased viability with paclitaxel GR00179-A-1 8.92 MAPK3 SP1
3 Decreased viability with paclitaxel GR00179-A-3 8.92 MAPK3 SP1

MGI Mouse Phenotypes related to Adrenal Cortical Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 CBL EGF MAPK3 PTEN SPRY1 SPRY2
2 integument MP:0010771 9.7 CBL EGF MAPK3 MME PTEN SH3KBP1
3 liver/biliary system MP:0005370 9.43 CBL DECR1 MAPK3 MME PTEN SP1
4 neoplasm MP:0002006 9.02 BAD MAPK3 PTEN SPRY1 SPRY2

Drugs & Therapeutics for Adrenal Cortical Adenocarcinoma

Drugs for Adrenal Cortical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
2
Racepinephrine Approved Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Mitotane Approved Phase 3,Phase 2 53-19-0 4211
7
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
8
Lenograstim Approved, Investigational Phase 3 135968-09-1
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
11
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
12
Etomidate Approved Phase 3,Phase 1,Phase 2 33125-97-2 36339 667484
13
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
14
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
18 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
19 Epinephryl borate Phase 3,Phase 2,Phase 1,Not Applicable
20 insulin Phase 3,Phase 2
21 Insulin, Globin Zinc Phase 3,Phase 2
22 Mitogens Phase 3,Phase 2
23 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
24 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Hormonal Phase 3,Phase 2
26 Etoposide phosphate Phase 3,Phase 2
27 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
28 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
29 Adjuvants, Anesthesia Phase 3
30 Analgesics Phase 3
31 Analgesics, Opioid Phase 3
32 Anesthetics Phase 3,Phase 1,Phase 2
33 Anesthetics, General Phase 3,Phase 1,Phase 2
34 Anesthetics, Intravenous Phase 3,Phase 1,Phase 2
35 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
36 Narcotics Phase 3
37 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
38 Adrenocorticotropic Hormone Phase 3,Phase 2
39 beta-endorphin Phase 3
40 Contraceptive Agents Phase 3,Phase 2
41 Contraceptives, Oral Phase 3
42 Contraceptives, Postcoital Phase 3
43 Cortisol succinate Phase 3,Phase 2
44 Hormone Antagonists Phase 3,Phase 2
45 Hormones Phase 3,Phase 2
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
47 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2
48 Hydrocortisone acetate Phase 3,Phase 2
49 Luteolytic Agents Phase 3
50 Melanocyte-Stimulating Hormones Phase 3

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
2 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
3 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
6 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
7 Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Recruiting NCT00777244 Phase 3 MITOTANE
8 Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia Recruiting NCT02010957 Phase 3
9 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
10 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Not yet recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
11 Sunitinib in Refractory Adrenocortical Carcinoma Unknown status NCT00453895 Phase 2 Sunitinib
12 Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
13 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
14 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
15 Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
16 Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
17 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
18 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
19 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
20 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
21 A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Completed NCT01262235 Phase 1, Phase 2 TKM-080301
22 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
23 A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent Completed NCT00264433 Phase 2 ADH -1 (Exherin™)
24 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
25 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
26 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
27 Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
28 Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
29 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
30 Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Recruiting NCT02673333 Phase 2 Pembrolizumab
31 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Recruiting NCT02468193 Phase 2 Osilodrostat
32 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
33 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
34 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
35 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
36 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
37 Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Active, not recruiting NCT02720484 Phase 2 Nivolumab
38 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Active, not recruiting NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
39 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Active, not recruiting NCT02804750 Phase 2 CORT125134
40 S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
41 IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated NCT00778817 Phase 2 mitotane
42 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
43 Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Withdrawn NCT00469469 Phase 2 Bevacizumab
44 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
45 Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
46 A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Completed NCT01981525 Phase 1 Metformin
47 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
48 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
49 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer Completed NCT00436657 Phase 1 CHPP of Cisplatin
50 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib

Search NIH Clinical Center for Adrenal Cortical Adenocarcinoma

Genetic Tests for Adrenal Cortical Adenocarcinoma

Anatomical Context for Adrenal Cortical Adenocarcinoma

MalaCards organs/tissues related to Adrenal Cortical Adenocarcinoma:

41
Cortex, Adrenal Gland, Adrenal Cortex, Liver, Bone, Testes, Brain

Publications for Adrenal Cortical Adenocarcinoma

Articles related to Adrenal Cortical Adenocarcinoma:

(show top 50) (show all 629)
# Title Authors Year
1
Co-culture of H295R Adrenocortical Carcinoma and BeWo Choriocarcinoma Cells to Study Feto-placental Interactions: Focus on Estrogen Biosynthesis. ( 29197012 )
2018
2
Adrenocortical carcinoma characterized by gynecomastia: A case report. ( 29403152 )
2018
3
Synchronous adrenocortical carcinoma and ovarian malignant mixed germ cell tumor: A case report and literature review. ( 29768344 )
2018
4
Ectopic, retroperitoneal adrenocortical carcinoma in the setting of Lynch syndrome. ( 28940135 )
2017
5
RARRES2 functions as a tumor suppressor by promoting I^-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma. ( 28114280 )
2017
6
Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. ( 28127763 )
2017
7
Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. ( 28270555 )
2017
8
Feminizing Adrenocortical Carcinoma Without Gynecomastia. ( 28804590 )
2017
9
Lung adenocarcinoma and adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1. ( 28070481 )
2017
10
Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome Combined With Adrenocortical Carcinoma on 18F-FDG PET/CT. ( 28737576 )
2017
11
Comparison of the methods for measuring the Ki-67 labeling index in adrenocortical carcinoma: manual versus digital image analysis. ( 26980031 )
2016
12
Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. ( 26671975 )
2016
13
Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis. ( 27589897 )
2016
14
Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. ( 27535174 )
2016
15
Chylous ascites after resection of giant adrenocortical carcinoma. ( 28149812 )
2016
16
Familial adrenocortical carcinoma in association with Lynch syndrome. ( 27144940 )
2016
17
Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. ( 27631436 )
2016
18
Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas. ( 27598485 )
2016
19
Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression. ( 26673009 )
2016
20
Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma. ( 27105537 )
2016
21
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma. ( 26771706 )
2016
22
Combined steroidogenic characters of fetal adrenal and Leydig cells in childhood adrenocortical carcinoma. ( 26940356 )
2016
23
First case report of an adrenocortical carcinoma caused by a BRCA2 mutation. ( 27603373 )
2016
24
5th International ACC Symposium: Surgical Considerations in the Treatment of Adrenocortical Carcinoma: 5th International ACC Symposium Session: Who, When and What Combination? ( 26728469 )
2016
25
Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma. ( 27336360 )
2016
26
Open Versus Laparoscopic Adrenalectomy for Adrenocortical Carcinoma: A Meta-analysis of Surgical and Oncological Outcomes. ( 26480850 )
2015
27
Management of adrenocortical carcinoma. ( 26477988 )
2015
28
Adrenocortical carcinoma with renal vein tumor thrombus extension. ( 25703915 )
2015
29
Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. ( 25979380 )
2015
30
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. ( 25795408 )
2015
31
Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. ( 25767716 )
2015
32
Androgen secreting giant adrenocortical carcinoma with no metastases: A case report and review of the literature. ( 26425231 )
2015
33
18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma. ( 26346137 )
2015
34
Factors associated with survival in pediatric adrenocortical carcinoma: An analysis of the National Cancer Data Base (NCDB). ( 26572849 )
2015
35
Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. ( 26282167 )
2015
36
Repeated resections for liver metastasis from primary adrenocortical carcinoma: A case report. ( 25765741 )
2015
37
Pure aldosterone-secreting adrenocortical carcinoma in a patient with refractory primary hyperaldosteronism. ( 26273475 )
2015
38
Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. ( 25559399 )
2015
39
First Case Report of a Sporadic Adrenocortical Carcinoma With Gastric Metastasis and a Synchronous Gastrointestinal Stromal Tumor of the Stomach. ( 26376405 )
2015
40
Chromosome 19 amplification correlates with advanced disease in adrenocortical carcinoma. ( 26453132 )
2015
41
Pregnancy in women previously treated for an adrenocortical carcinoma. ( 26461265 )
2015
42
DNA copy amplification andA overexpression of SLC12A7 inA adrenocortical carcinoma. ( 26454676 )
2015
43
Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Population-Based Study. ( 26510563 )
2015
44
Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. ( 26305886 )
2015
45
Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers. ( 25657202 )
2015
46
Inhibition of IGF-1R in adrenocortical carcinoma. ( 25795411 )
2015
47
Estrogen related receptor I+ (ERRI+) a promising target for the therapy of adrenocortical carcinoma (ACC). ( 26312764 )
2015
48
CUSHING'S SYNDROME CAUSED BY AN ADRENOCORTICAL CARCINOMA AFTER A BARIATRIC SURGERY: CASE REPORT. ( 26537284 )
2015
49
Low DICER1 expression is associated with poor clinical outcome in adrenocortical carcinoma. ( 26087193 )
2015
50
Adrenocortical carcinoma with inferior vena cava, left renal vein and right atrium tumor thrombus extension. ( 26355237 )
2015

Variations for Adrenal Cortical Adenocarcinoma

Expression for Adrenal Cortical Adenocarcinoma

Search GEO for disease gene expression data for Adrenal Cortical Adenocarcinoma.

Pathways for Adrenal Cortical Adenocarcinoma

Pathways related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 BAD CBL EGF MAPK3 PTEN RPS6KA1
2
Show member pathways
13.9 BAD CBL EGF MAPK3 MME PTEN
3
Show member pathways
13.33 BAD CBL EGF MAPK3 PTEN SH3KBP1
4
Show member pathways
13.15 BAD CBL EGF MAPK3 RPS6KA1
5
Show member pathways
12.81 BAD CBL EGF MAPK3 PTEN RPS6KA1
6
Show member pathways
12.8 BAD CBL MAPK3 PTEN RPS6KA1
7
Show member pathways
12.79 BAD EGF MAPK3 PTEN
8
Show member pathways
12.76 BAD CBL EGF MAPK3 PTEN
9
Show member pathways
12.75 BAD MAPK3 PTEN RPS6KA1
10 12.72 BAD CBL EGF MAPK3 PTEN SP1
11
Show member pathways
12.68 BAD CBL MAPK3 PTEN SP1
12
Show member pathways
12.68 BAD EGF MAPK3 PTEN RPS6KA1 SP1
13
Show member pathways
12.66 BAD EGF MAPK3 PTEN SP1
14
Show member pathways
12.61 BAD CBL EGF MAPK3 PTEN SH3KBP1
15
Show member pathways
12.58 BAD CBL MAPK3 PTEN RPS6KA1 SH3KBP1
16
Show member pathways
12.56 CBL MAPK3 PTEN SP1
17
Show member pathways
12.48 BAD CBL MAPK3 PTEN
18
Show member pathways
12.48 BAD CBL EGF MAPK3 RPS6KA1
19
Show member pathways
12.42 CBL MAPK3 PTEN RPS6KA1
20
Show member pathways
12.4 BAD MAPK3 RPS6KA1
21
Show member pathways
12.39 BAD CBL EGF MAPK3 SP1
22
Show member pathways
12.37 BAD CBL EGF MAPK3 PTEN SP1
23
Show member pathways
12.35 BAD CBL MAPK3 RPS6KA1
24
Show member pathways
12.35 BAD CBL MAPK3 RPS6KA1 SP1
25
Show member pathways
12.3 BAD CBL MAPK3 PTEN RPS6KA1 SP1
26
Show member pathways
12.29 CBL MAPK3 PTEN RPS6KA1
27
Show member pathways
12.22 EGF MAPK3 RPS6KA1
28
Show member pathways
12.16 CBL MAPK3 SPRY2
29
Show member pathways
12.12 MAPK3 RPS6KA1 SP1
30
Show member pathways
12.06 CBL EGF MAPK3 PTEN
31
Show member pathways
12.06 BAD CBL MAPK3 PTEN RPS6KA1
32 12.05 BAD PTEN SP1
33 12.02 BAD MAPK3 RPS6KA1
34
Show member pathways
11.99 EGF MAPK3 PTEN
35
Show member pathways
11.98 CBL MAPK3 RPS6KA1
36
Show member pathways
11.98 BAD MAPK3 PTEN RPS6KA1
37 11.97 CBL EGF SH3KBP1 SPRY1 SPRY2
38 11.96 BAD EGF MAPK3
39 11.95 BAD MAPK3 PTEN
40
Show member pathways
11.93 BAD MAPK3 RPS6KA1
41 11.88 EGF MAPK3 PTEN
42 11.83 BAD EGF MAPK3
43 11.71 BAD MAPK3 RPS6KA1 SPRY1 SPRY2
44 11.62 EGF MAPK3 SP1
45 11.41 BAD EGF MAPK3
46 11.41 CBL MAPK3 RPS6KA1 SPRY2
47 11.38 CBL EGF PTEN RPS6KA1 SH3KBP1 SP1
48
Show member pathways
11.32 CBL EGF SH3KBP1 SPRY1 SPRY2
49 11.22 BAD MAPK3
50 11.21 MAPK3 SP1

GO Terms for Adrenal Cortical Adenocarcinoma

Cellular components related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.85 BAD CBL MAPK3 MME PTEN RPS6KA1
2 cytosol GO:0005829 9.61 BAD CBL DECR1 MAPK3 PTEN RPS6KA1
3 focal adhesion GO:0005925 8.92 CBL MAPK3 MME SH3KBP1

Biological processes related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.87 CBL PTEN RPS6KA1 SPRY2
2 apoptotic process GO:0006915 9.77 BAD MAPK3 PTEN RPS6KA1 SH3KBP1
3 membrane organization GO:0061024 9.63 CBL EGF SH3KBP1
4 response to ethanol GO:0045471 9.58 BAD CBL PTEN
5 branching morphogenesis of an epithelial tube GO:0048754 9.56 EGF SPRY2
6 ERK1 and ERK2 cascade GO:0070371 9.55 EGF MAPK3
7 negative regulation of Ras protein signal transduction GO:0046580 9.54 SPRY1 SPRY2
8 animal organ development GO:0048513 9.52 SPRY1 SPRY2
9 lung morphogenesis GO:0060425 9.51 MAPK3 SPRY2
10 negative regulation of fibroblast growth factor receptor signaling pathway GO:0040037 9.49 SPRY1 SPRY2
11 establishment of mitotic spindle orientation GO:0000132 9.48 SPRY1 SPRY2
12 positive regulation of ubiquitin-dependent protein catabolic process GO:2000060 9.43 EGF PTEN
13 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.43 PTEN SPRY1 SPRY2
14 positive regulation of gene expression GO:0010628 9.35 EGF MAPK3 PTEN SP1 SPRY2
15 bud elongation involved in lung branching GO:0060449 9.32 SPRY1 SPRY2
16 negative regulation of neurotrophin TRK receptor signaling pathway GO:0051387 9.16 SPRY1 SPRY2
17 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.02 CBL EGF SH3KBP1 SPRY1 SPRY2

Molecular functions related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.26 BAD CBL PTEN SPRY2
2 epidermal growth factor receptor binding GO:0005154 9.16 CBL EGF
3 protein tyrosine kinase binding GO:1990782 8.62 CBL PTEN

Sources for Adrenal Cortical Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....